Loading...
Login/Register
Welcome
Profile
Log Off
text
title
chapter title
keyword
WHO Home
WHO Health Systems and Services
WHO Medicines
WHO sites
Medicines Documentation home
Search
Titles A-Z
Subjects
Keywords
Series and Periodicals
Publishers
Authors A-Z
Regions
Countries
Index
Sub-collections
Public
sub-collections
Expand Document
|
Expand Chapter
|
Full TOC
|
Printable HTML version
::
Themes & Keywords
·
Keywords
>
pharmaceuticals newsletter
WHO Pharmaceuticals Newsletter 1999, No. 01&02
(1999; 16 pages)
Table of Contents
Regulatory actions
Albumin (human): batches withdrawn: increase in aluminium level: Germany
Alfalfa products: caution label: Malaysia
Amineptine: marketing authorization suspended: drug abuse and dependence: France
Astemizole: OTC formulations withdrawn: UK
Cisapride: restricted indications: Ireland
Dronabinol: proposed reclassificaion from Schedule II to Schedule III of the US Controlled Substances Act: USA
Entacapone: revised product information: caution concerning use: EMEA
Furazolidone: withdrawn: Yemen
Ginkgo biloba parenteral infusion formulation: suspension further extended: Germany
Isotretinoin: revised prescribing information: depression: Ireland
Kaolin and pectin suspension: withdrawn: Yemen
Levocarnitine: revised data sheet: seizures: USA
Loratadine/pseudoephedrine sulfate: reformulated: UK
Metamizole sodium: withdrawn due to agranulocytosis: Yemen
Methadone mixture: child-resistant packaging recommended: Germany
Methylrosanilinium chloride (Gentian violet): withdrawn: Malaysia
Montelukast: revised data sheet: eosinophilia: UK
Drug surveillance
Acarbose: hepatitis: France, Spain
Corticosteroid-induced osteoporosis: guidelines available: UK
Hydroxycarbamide: leg ulcers: review: France
Measles/mumps/rubella (MMR) vaccine: no evidence of link with inflammatory bowel disease and/or autism: Ireland
Mercury compounds: call for data: USA
Nefazodone: review of adverse reactions: Australia
Ondansetron: chest pain: Australia
Psorigon skin products: update: further analysis confirms tretinoin content: Germany
New developments
Abacavir: approved for HIV-1 infection: USA
Acetylsalicylic acid: approved for use in cardiovascular and cerebrovascular conditions: USA
Celecoxib: approved for treatment of rheumatoid arthritis and osteoarthritis: USA
Cilostazol: approved for treatment of stable intermittent claudication: USA
Interferon alfa-2b and ribavirin combination therapy: indications extended: previously untreated hepatitis C patients: USA
New formulations
Newly approved products
Medical devices
CFC-free aerosol inhalers (MDIs): update: Malaysia
Laser for blood tests: approved for home use in diabetic patients: USA
General information
Medical devices containing material derived from animal sources: guidance document available: USA
Paediatric pharmacokinetic studies: draft guidance available: USA
Medication errors
Decimal dosages: confusion: USA
Eltroxin (levothyroxine sodium): confusion in formulations: Ireland
Pegaspargase (Oncaspar): misleading graphics: USA
Remeron (mirtazepine): strength confusion: USA
Tiagabine and tizanidine: name confusion and similar dosing and tablet strength: USA
Warfarin (Coumadin): confusing instructions: USA
Veterinary medicine
Carbaril in veterinary medicines: temporary suspension extended: Germany
Chlortetracycline and salinomycin: approved in broiler chickens for prevention of coccidiosis: USA
Organophosphate products: instructions for handling: Ireland
WHO Pharmaceuticals Newsletter 1999, No. 01&02
Essential Drugs and Medicines Policy
WHO.INT
World Health Organization
Contacts
|
E-mail scams
|
Employment
|
FAQs
|
Feedback
|
Privacy
|
RSS feeds
© WHO 2013
Last updated: May 3, 2013
Loading...
